Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis
Interventions: Remicade; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Blood Volume Analysis
Interventions: 1mL of I-131 Human Serum Albumin is injected prior to the measurements; Radiation
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 50 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Aging
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 65 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Spinal Injuries, Spinal Deformity
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: San Francisco, California • Louisville, Kentucky • New York, New York + 1 more

Conditions: HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions: nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy; Drug · Procedure · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI); Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
Interventions: cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation; Drug · Procedure · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung, Metastatic Uveal Melanoma
Interventions: ADV/HSV-tk, Valacyclovir, SBRT, nivolumab; Biological · Drug · Radiation
Lead sponsor: Eric Bernicker, MD; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma, EBV-Related PTLD, Hodgkin Lymphoma, EBV Related Non-Hodgkin's Lymphoma, EBV Related Hodgkin's Lymphoma
Interventions: EBVST Cells, Nivolumab; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Pre-Eclampsia
Interventions: Human Albumin (colloid), Lactated Ringer's Injection (crystalloid), Edwards HemoSphere monitor with ClearSight-Acumen finger cuff; Drug · Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Blood Volume, Total Blood Volume, Exercise Capacity Test - Bicycle, Posture Study; Radiation · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions: SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H; Device
Lead sponsor: Peerbridge Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 15,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Blood Loss, Surgical
Interventions: Vasopressin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Emphysema
Interventions: Treatment plus Optimal Medical Therapy, Optimal Medical Therapy; Device · Other
Lead sponsor: Aeris Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Interventions: extracorporeal photopheresis; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Iron Deficiency Anemia, Inflammatory Bowel Disease
Interventions: Intravenous iron sucrose, Oral ferrous sulfate; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome
Interventions: Autonomic Function Testing, Saline infusions, L-NMMA trimethaphan, methyldopa; Other · Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atrial Fibrillation, Post-Op Complication
Interventions: CardiaMend in Combination with Amiodarone; Combination Product
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: Omalizumab, Placebo, Fluticasone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 56
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more

Conditions: Head and Neck Cancer
Interventions: ENI using IMRT with or without chemotherapy, INRT, ENI; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lung Cancer (Diagnosis)
Interventions: Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cancer, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions: Fludarabine, Cyclophosphamide, Transplantation; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 4 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy

Blood Volume Analysis of Total Hip Arthroplasty Patients Under Hypotensive Anesthesia

Angiotensin-(1-7) Cardiovascular Effects in Aging

Tranexamic Acid to Reduce Blood Loss in Spine Surgery

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia

Dietary Salt in Postural Tachycardia Syndrome

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

Metabolic Effects of Angiotensin-(1-7)

Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease

IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD

Autonomic Nervous System and Chronic Fatigue Syndrome

Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy